Unnamed: 0,title,date,stock,sentiment
107092.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,ATRC,positive
107093.0,Stocks That Hit 52-Week Highs On Monday,2020-05-18 10:44:00-04:00,ATRC,neutral
107094.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,ATRC,positive
107095.0,Stocks That Hit 52-Week Highs On Wednesday,2020-05-13 10:35:00-04:00,ATRC,neutral
107096.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,ATRC,neutral
107097.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,ATRC,neutral
107098.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,ATRC,negative
107099.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,ATRC,neutral
107100.0,AtriCure Announces $100M Common Stock Offering,2020-05-11 07:55:00-04:00,ATRC,neutral
107101.0,ArtiCure Announcds $100M Common Stock Offering,2020-05-11 07:53:00-04:00,ATRC,neutral
107102.0,"Oppenheimer Maintains Outperform on AtriCure, Raises Price Target to $52",2020-05-11 07:39:00-04:00,ATRC,neutral
107103.0,"SVB Leerink Reiterates Outperform on AtriCure, Raises Price Target to $55",2020-05-11 06:16:00-04:00,ATRC,neutral
107104.0,AtriCure Reports Results From CONVERGE IDE Trial: 'study met primary effectiveness endpoint of superiority in favor of the hybrid Convergent procedure',2020-05-08 08:48:00-04:00,ATRC,positive
107105.0,"Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $45",2020-04-30 12:35:00-04:00,ATRC,neutral
107106.0,"AtriCure Q1 EPS $(0.420) Misses $(0.410) Estimate, Sales $53.225M Miss $55.500M Estimate",2020-04-29 16:03:00-04:00,ATRC,negative
107107.0,"The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda",2020-04-29 08:40:00-04:00,ATRC,positive
107108.0,"JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $39",2020-04-28 10:53:00-04:00,ATRC,negative
107109.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,ATRC,negative
107110.0,"Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $41",2020-04-13 12:36:00-04:00,ATRC,negative
107111.0,AtriCure Announces CONVERGE IDE Trial Results Accepted For Late-Breaking Clinical Trial Sessions At Annual Heart Rhythm Society (HRS) Meeting,2020-04-13 08:01:00-04:00,ATRC,positive
107112.0,AtriCure Inc Withdraws Its Previously Announced Financial Guidance For 2020,2020-04-09 08:09:00-04:00,ATRC,neutral
107113.0,AtriCure Sees Prelim. Q1 Sales $53.2M vs $59.84M Est.,2020-04-09 08:06:00-04:00,ATRC,neutral
107114.0,"Benzinga's Top Upgrades, Downgrades For April 7, 2020",2020-04-07 09:41:00-04:00,ATRC,positive
107115.0,"Oppenheimer Initiates Coverage On AtriCure with Outperform Rating, Announces Price Target to $45",2020-04-07 05:23:00-04:00,ATRC,neutral
107116.0,"BTIG Research Maintains Buy on AtriCure, Raises Price Target to $48",2020-02-19 08:18:00-05:00,ATRC,neutral
107117.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,ATRC,negative
107118.0,"Needham Maintains Buy on AtriCure, Raises Price Target to $52",2020-02-19 06:10:00-05:00,ATRC,neutral
107119.0,AtriCure Sees FY20 EPS $(1.14)-$(1.24) Vs. $(1.09) Est.,2020-02-18 16:03:00-05:00,ATRC,neutral
107120.0,"AtriCure Q4 EPS $(0.37) Beats $(0.41) Estimate, Sales $61.3M Beat $59.5M Estimate",2020-02-18 16:02:00-05:00,ATRC,neutral
107121.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-18 11:03:00-05:00,ATRC,neutral
107122.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,ATRC,positive
107123.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,ATRC,negative
107124.0,"The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO",2020-02-13 08:05:00-05:00,ATRC,negative
107125.0,Stocks That Hit 52-Week Highs On Wednesday,2020-02-12 11:45:00-05:00,ATRC,neutral
107126.0,"The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data",2020-02-12 09:18:00-05:00,ATRC,positive
107127.0,Stocks That Hit 52-Week Highs On Tuesday,2020-02-11 10:17:00-05:00,ATRC,neutral
107128.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,ATRC,positive
107129.0,Stocks That Hit 52-Week Highs On Monday,2020-02-10 10:25:00-05:00,ATRC,neutral
107130.0,"The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",2020-01-31 09:09:00-05:00,ATRC,negative
107131.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-30 10:25:00-05:00,ATRC,neutral
107132.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,ATRC,positive
107133.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-29 10:16:00-05:00,ATRC,neutral
107134.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,ATRC,neutral
107135.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-28 11:05:00-05:00,ATRC,neutral
107136.0,"Needham Maintains Buy on AtriCure, Raises Price Target to $48",2020-01-24 06:18:00-05:00,ATRC,neutral
107137.0,"The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment",2020-01-23 07:24:00-05:00,ATRC,positive
107138.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-22 10:17:00-05:00,ATRC,neutral
107139.0,"The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings",2020-01-22 08:25:00-05:00,ATRC,neutral
107140.0,Stocks That Hit 52-Week Highs On Tuesday,2020-01-21 10:11:00-05:00,ATRC,neutral
107141.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,ATRC,neutral
107142.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,ATRC,negative
107143.0,Stocks That Hit 52-Week Highs On Thursday,2020-01-16 10:22:00-05:00,ATRC,neutral
107144.0,"The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics",2020-01-16 07:22:00-05:00,ATRC,neutral
107145.0,Stocks That Hit 52-Week Highs On Wednesday,2020-01-15 13:14:00-05:00,ATRC,neutral
107146.0,"The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance",2020-01-15 08:22:00-05:00,ATRC,negative
107147.0,AtriCure Sees Q4 Sales $61.3M vs $59.24M Est,2020-01-13 08:03:00-05:00,ATRC,neutral
107148.0,Stocks That Hit 52-Week Highs On Friday,2020-01-10 12:18:00-05:00,ATRC,neutral
107149.0,AtriCure Announces Successful Completion of Patient Enrollment of aMAZE Clinical Trial and FDA Approval of Continued Access Protocol,2020-01-07 08:11:00-05:00,ATRC,positive
107150.0,AtriCure Raises FY19 Sales Guidance From $224M-$228M To $227M-$229M vs $227.45M Est.,2019-10-30 16:54:00-04:00,ATRC,neutral
107151.0,"AtriCure Q3 EPS $(0.25) Beats $(0.27) Estimate, Sales $56.6M Beat $55.23M Estimate",2019-10-30 16:50:00-04:00,ATRC,neutral
107152.0,"The Daily Biotech Pulse: Novartis Program Placed On Partial Clinical Hold, Adcom Snub For Amag, Amgen Earnings",2019-10-30 07:01:00-04:00,ATRC,negative
107153.0,86 Biggest Movers From Yesterday,2019-09-06 05:06:00-04:00,ATRC,negative
107154.0,AtriCure shares trading lower following a negative report from Culpers Research.,2019-09-05 14:08:00-04:00,ATRC,negative
107155.0,"'AtriCure (ATRC): 57% Downside on a Maze of Highly Paid Doctors, Off-Label Device Usage, and Ongoing DOJ Investigation' Report From Culper Research",2019-09-05 10:02:00-04:00,ATRC,negative
107156.0,Stocks That Hit 52-Week Lows On Wednesday,2019-09-04 11:39:00-04:00,ATRC,negative
107157.0,"AtriCure Enters Into Definitive Agreement to Acquire SentreHEART; Upfront Payment of $40M in Cash and Stock, Up to $260M in Contingent Consideration",2019-08-12 05:58:00-04:00,ATRC,positive
107158.0,AtriCure Sees FY19 Sales $224M-$228M vs $226.46M Est.,2019-07-30 16:26:00-04:00,ATRC,neutral
107159.0,"AtriCure Q2 EPS $(0.17) Beats $(0.18) Estimate, Sales $58.9M Beat $57.76M Estimate",2019-07-30 16:25:00-04:00,ATRC,neutral
107160.0,"The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings",2019-07-30 07:00:00-04:00,ATRC,positive
107161.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,ATRC,negative
107162.0,AtriCure Sees FY19 Sales $222M-$228M vs $225.84M Est.,2019-04-25 16:46:00-04:00,ATRC,neutral
107163.0,"AtriCure Q1 Adj, EPS $(0.2) Beats $(0.24) Estimate, Sales $54M Beat $52.36M Estimate",2019-04-25 16:45:00-04:00,ATRC,neutral
107164.0,"The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings",2019-04-25 07:58:00-04:00,ATRC,neutral
107165.0,AtriCure Reports First Patient Enrolled In DEEP IDE Trial Report,2019-04-23 08:05:00-04:00,ATRC,neutral
107166.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-04-21 14:06:00-04:00,ATRC,neutral
107167.0,"JP Morgan Initiates Coverage On AtriCure with Overweight Rating, Announces $37 Price Target",2019-04-12 07:31:00-04:00,ATRC,neutral
107168.0,"Benzinga's Top Upgrades, Downgrades For April 2, 2019",2019-04-02 09:13:00-04:00,ATRC,positive
107169.0,"BTIG Research Upgrades AtriCure to Buy, Announces $35",2019-04-02 06:45:00-04:00,ATRC,neutral
107170.0,"AtriCure Filing Shows Registration For Mixed Securities Offering, Including ~5.67M Shares Via Selling Shareholders",2019-03-01 12:35:00-05:00,ATRC,positive
107171.0,"AtriCure Sees FY19 EPS $(0.78)-$(0.68) vs $(0.58) Est., Sales $220M-$228M vs $223.45M Est.",2019-02-28 17:08:00-05:00,ATRC,neutral
107172.0,"AtriCure Q4 EPS $(0.09) Beats $(0.17) Estimate, Sales $52.89M Beat $51.56M Estimate",2019-02-28 17:06:00-05:00,ATRC,neutral
107173.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,ATRC,positive
107174.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,ATRC,neutral
107175.0,AtriCure Reports The Society of Thoracic Surgeons Endorsed Co.'s Advanced Ablation Courses In US,2019-02-19 08:14:00-05:00,ATRC,positive
107176.0,AtriCure Sees FY2019 Sales $220.0M-228.0M vs $222.80M Est,2019-01-07 08:32:00-05:00,ATRC,neutral
107177.0,AtriCure Sees FY2018 Sales $201.60M vs $200.02M Est,2019-01-07 08:31:00-05:00,ATRC,neutral
107178.0,"AtriCure Sees FY18 EPS $(0.74)-$(0.69) vs $(0.69) Est., Sales $198M-$201M vs $197.91M Est.",2018-11-01 16:29:00-04:00,ATRC,neutral
107179.0,"AtriCure, Inc. Q3 Adj. EPS $(0.24) Misses $(0.21) Estimate, Sales $49.9M Beat $47.72M Estimate",2018-11-01 16:28:00-04:00,ATRC,negative
107180.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,ATRC,negative
107181.0,"Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $40",2018-10-09 07:12:00-04:00,ATRC,neutral
107182.0,46 Biggest Movers From Friday,2018-10-08 04:46:00-04:00,ATRC,neutral
107183.0,36 Stocks Moving In Friday's Mid-Day Session,2018-10-05 12:37:00-04:00,ATRC,neutral
107184.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,ATRC,positive
107185.0,AtriCure Late Thursday Announced It Will Price Its 2.5M Share Common Stock Offering At $30.75/Share,2018-10-05 07:55:00-04:00,ATRC,positive
107186.0,"The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut",2018-10-04 07:59:00-04:00,ATRC,neutral
107187.0,"AtriCure Sees Q3 Sales ~$49.9M vs $46.8M Estimate, Loss $6M-$7.5M",2018-10-03 16:02:00-04:00,ATRC,negative
107188.0,AtriCure Reports 2.5M Share Common Stock Offering,2018-10-03 16:01:00-04:00,ATRC,positive
107189.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,ATRC,neutral
107190.0,"The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding",2018-09-21 08:51:00-04:00,ATRC,negative
107191.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,ATRC,neutral
107192.0,"Stocks Which Set New 52-Week High Yesterday, September 19th",2018-09-20 11:24:00-04:00,ATRC,neutral
107193.0,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",2018-09-20 09:02:00-04:00,ATRC,positive
107194.0,"Stocks Which Set New 52-Week High Yesterday, September 4th",2018-09-05 10:22:00-04:00,ATRC,neutral
107195.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,ATRC,neutral
107196.0,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",2018-08-28 08:13:00-04:00,ATRC,neutral
107197.0,"Stocks Which Set New 52-Week High Friday, August 24th",2018-08-27 09:24:00-04:00,ATRC,neutral
107198.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,ATRC,neutral
107199.0,"Stocks Which Set New 52-Week High Yesterday, August 22nd",2018-08-23 10:51:00-04:00,ATRC,neutral
107200.0,"Stocks Which Set New 52-Week High Yesterday, August 2nd",2018-08-03 11:16:00-04:00,ATRC,neutral
107201.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,ATRC,neutral
107202.0,AtriCure Sees FY18 Sales $193M-$197M vs $194.96M Est.,2018-08-01 16:09:00-04:00,ATRC,neutral
107203.0,"AtriCure Q2 EPS $(0.01) Beats $(0.23) Estimate, Sales $51.8M Beat $49.9M Estimate",2018-08-01 16:08:00-04:00,ATRC,neutral
107204.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,ATRC,negative
107205.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,ATRC,neutral
107206.0,32 Stocks Moving In Friday's Pre-Market Session,2018-07-20 08:14:00-04:00,ATRC,neutral
107207.0,"Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading",2018-06-20 08:36:00-04:00,ATRC,negative
107208.0,25 Stocks Moving In Friday's Pre-Market Session,2018-06-15 08:16:00-04:00,ATRC,neutral
107209.0,"AtriCure, Baheal Group Establish Partnership and China Distribution Agreement",2018-06-05 06:03:00-04:00,ATRC,positive
107210.0,AtriCure Reiterates FY18 Sales Guidance of $190M-$196M vs $193.79M Est.,2018-04-26 17:01:00-04:00,ATRC,neutral
107211.0,"AtriCure Q1 EPS $(0.31) Misses $(0.27) Est., Sales $47M Beats $45.46M Est.",2018-04-26 17:01:00-04:00,ATRC,negative
107212.0,AtriCure 10-K Shows Co. Received A Civil Investigative Demand From The Dept. Of Justice To Determine Whether The Co. Violated The False Claims Act,2018-02-28 13:30:00-05:00,ATRC,negative
107213.0,"AtriCure Sees FY18 Sales $190M-$196M vs $194.4M Est., Adj. EBITDA Positive",2018-02-26 16:28:00-05:00,ATRC,positive
107214.0,"AtriCure Reports Q4 EPS $(0.08) vs $(0.27) In Same Qtr. Last Year, Adj. EBITDA Loss $300K, Sales $46.1M vs $45.4M Est.",2018-02-26 16:28:00-05:00,ATRC,negative
107215.0,AtriCure Q4 Earnings Outlook,2018-02-26 11:27:00-05:00,ATRC,neutral
107216.0,Atricure Sees FY18 Sales ~$190M-$196M vs $195.8M Est.,2018-01-08 08:52:00-05:00,ATRC,neutral
107217.0,"AtriCure Sees Q4 Sales ~$46.1M vs $45.2M Est.; Sees FY17 Sales $174.7M vs $173.9M Est., Adj. EBITDA Loss $4M-$6M",2018-01-08 08:51:00-05:00,ATRC,negative
107218.0,"AtriCure Sees Q4 Sales $43.5M to $46.5M vs $43.44M Est.; Lowers FY 2017 Sales Guidance From $177M-$178M to $172M-$175M vs $177M Est., Reaffirms FY 2017 EPS Guidance",2017-11-01 17:52:00-04:00,ATRC,negative
107219.0,"AtriCure Q3 EPS $(0.22) vs $(0.24) Est., Sales $42.2M vs $43.4M Est.",2017-11-01 17:49:00-04:00,ATRC,neutral
107220.0,AtriCure Sees FY17 Sales $177M-$178M vs $175.95M Est.,2017-07-27 16:58:00-04:00,ATRC,neutral
107221.0,"AtriCure Reports Q2 EPS $(0.21) vs $(0.26) Est., Sales $45.2M vs $44.21M",2017-07-27 16:58:00-04:00,ATRC,neutral
107222.0,AtriCure Names Salvatore Privitera CTO,2017-07-18 16:17:00-04:00,ATRC,neutral
107223.0,"AtriCure Sees FY17 EPS $(1.04)-$(0.94), Sales $175M-$178M vs $175.5M Est.",2017-05-04 17:53:00-04:00,ATRC,neutral
107224.0,"AtriCure Reports Q1 EPS $(0.32) vs $(0.31) in Same Qtr. Last Year, Adj. EBITDA Loss $3.7M, Sales $41.3M vs $40.3M Est.",2017-05-04 17:52:00-04:00,ATRC,negative
107225.0,AtriCure Reports AtriClip Systemk Surpassed 100K Units Sold Globally,2017-04-25 08:00:00-04:00,ATRC,neutral
107226.0,Hearing Dealreporter Out With Report On Potential Sale Of Atricure,2017-03-07 11:02:00-05:00,ATRC,neutral
107227.0,15 Biggest Mid-Day Losers For Monday,2017-03-06 13:15:00-05:00,ATRC,negative
107228.0,Mid-Morning Market Update: Markets Open Lower; Deutsche Bank Plans to Raise Capital,2017-03-06 10:07:00-05:00,ATRC,negative
107229.0,BTIG Research Downgrades AtriCure To Neutral,2017-03-06 06:22:00-05:00,ATRC,neutral
107230.0,"AtriCure Reports Q4 EPS $(0.27) vs $(0.31) Est., Sales $41.2M vs $42.03M Est.",2017-02-28 16:33:00-05:00,ATRC,neutral
107231.0,AtriCure Sees FY16 Sales $155.1M vs $156M Est.,2017-02-03 08:01:00-05:00,ATRC,neutral
107232.0,AtriCure Reports Prelim. Q4 Sales ~$41.2M vs $42M Est.,2017-02-03 08:01:00-05:00,ATRC,neutral
107233.0,AtriCure Q4 Revenue $41.2M vs $42.8M Est,2017-01-09 08:08:00-05:00,ATRC,neutral
107234.0,Canaccord Genuity Medical Technology And Diagnostics Forum Today,2016-11-17 09:56:00-05:00,ATRC,neutral
107235.0,Stifel Healthcare Conference Today,2016-11-15 10:53:00-05:00,ATRC,neutral
107236.0,20 Biggest Mid-Day Gainers For Friday,2016-10-28 12:24:00-04:00,ATRC,neutral
107237.0,Mid-Morning Market Update: Markets Mostly Higher; Mastercard Beats Q3 Views,2016-10-28 10:02:00-04:00,ATRC,neutral
107238.0,"AtriCure Sees FY16 Rev. $156-$158M vs. Est. $156M, EPS $(1.16)-$(1.10) vs. Est. $(1.16)",2016-10-27 16:43:00-04:00,ATRC,neutral
107239.0,"AtriCure Reports Q3 EPS $(0.21) vs. Est. $(0.28), Rev. $38.3M vs. Est. $37.8M",2016-10-27 16:42:00-04:00,ATRC,neutral
107240.0,AtriCure Sees FY16 EPS $(1.22)-$(1.12) vs. Est. $(1.19),2016-08-04 16:23:00-04:00,ATRC,neutral
107241.0,"Atricure Reports Q2 EPS $(0.26) vs. Est. $(0.30), Rev. $39.7M vs. Est. $39.8M",2016-08-04 16:22:00-04:00,ATRC,neutral
107242.0,BMO Capital Highlights This Week's MedTech Earnings,2016-08-01 15:14:00-04:00,ATRC,neutral
107243.0,AtriCure Reports First Patient Enrollment in FROST Cryoanalgesia Study,2016-06-21 08:06:00-04:00,ATRC,neutral
107244.0,AtriCure Files $150M Mixed Securities Shelf Offering,2016-06-17 12:27:00-04:00,ATRC,positive
107245.0,AtriCure Sees FY16 EPS $(1.22)-$(1.12) vs. Est. $(1.19),2016-04-28 16:53:00-04:00,ATRC,neutral
107246.0,"AtriCure Reports Q1 EPS $(0.31) vs. Est. $(0.32), Rev. $35.9M vs. Est. $35.7M",2016-04-28 16:52:00-04:00,ATRC,neutral
107247.0,AtriCure Receives FDA Clearance for New AtriClip Device,2016-04-26 08:05:00-04:00,ATRC,neutral
107248.0,AtriCure Reports 510(k) Clearance for cryoFORM Probe,2016-04-12 08:00:00-04:00,ATRC,neutral
107249.0,"Northland Securities Initiates Coverage on AtriCure at Outperform, Announces $24.00 PT",2016-03-29 08:54:00-04:00,ATRC,positive
107250.0,"AtriCure Reports Q4 EPS $(0.36), Inline, Sales $35.9M vs $35.9M Est.",2016-02-23 16:00:00-05:00,ATRC,neutral
107251.0,AtriCure Sees Q4 Sales $35.90M vs $35.90M Est,2016-01-11 08:01:00-05:00,ATRC,neutral
107252.0,AtriCure Sees FY2015 Sales $129.80M vs $129.80M Est,2016-01-11 08:01:00-05:00,ATRC,neutral
107253.0,"Filing from AtriCure Shows Registration for Mixed Securities Shelf Offering, Including ~5.66M Common Shares",2015-11-10 13:37:00-05:00,ATRC,positive
107254.0,"AtriCure Inline Q3 Loss $0.22, Sales $31.4M Vs Est $31.38M; Sees FY 15 Rev $129.5M-$130.5M Vs Est $128.96M; Sees FY 16 Revs Up 25%",2015-10-27 16:21:00-04:00,ATRC,negative
107255.0,Morning Market Losers,2015-10-05 10:00:00-04:00,ATRC,negative
107256.0,"Must Watch Stocks for October 5, 2015",2015-10-05 04:48:00-04:00,ATRC,neutral
107257.0,AtriCure Narrows 2015 View to Revenue of $128M-$129M vs $127.63M Est,2015-10-04 18:34:00-04:00,ATRC,neutral
107258.0,"AtriCure to Acquire nContact for 3.7M Shares, $8M in Cash, Up to $50M in Contingent Consideration",2015-10-04 18:31:00-04:00,ATRC,positive
107259.0,Canaccord Analysts Recommend 'Aggressively Buying' AtriCure After Sell-Off,2015-09-29 08:45:00-04:00,ATRC,positive
107260.0,Benzinga's Top Initiations,2015-08-07 10:01:00-04:00,ATRC,positive
107261.0,"BTIG Research Initiates Coverage on AtriCure at Buy, Announces $34.00 PT",2015-08-07 08:33:00-04:00,ATRC,neutral
107262.0,"AtriCure Reports Q2 Sales $32.6M vs $30.5M Est., Loss of $0.18/Share vs Loss of $0.21/Share Est.; Raises FY15 Sales Guidance from $123.5M-$125.5M to $127M-$129M vs $124.5M Est.",2015-07-28 16:25:00-04:00,ATRC,negative
107263.0,"Atricure Reports Q1 EPS -$0.19 Vs Est -$0.21, Sales $29.9M vs Est $28.59M",2015-04-29 16:15:00-04:00,ATRC,neutral
107264.0,"Dougherty & Company Initiates Coverage on AtriCure at Buy, Announces $25.00 PT",2015-03-11 06:21:00-04:00,ATRC,neutral
107265.0,"Needham Initiates Coverage on AtriCure at Buy, Announces $21.00 PT",2015-03-09 06:07:00-04:00,ATRC,neutral
107266.0,"Needham Initiates Coverage on AtriCure at Buy, Announces $21.00 PT",2015-03-09 05:24:00-04:00,ATRC,neutral
107267.0,"Atricure Reports Q4 Loss of $0.20/Share, Inline, Sales $29.4M vs $29M Est.; Sees FY15 Sales $122.5M-$124.5M",2015-02-23 16:05:00-05:00,ATRC,negative
107268.0,Amended 13G: Thomson Horstmann Liquidates Stake In Atricure Inc.,2015-01-22 13:12:00-05:00,ATRC,neutral
107269.0,AtriCure Inc Appoints Douglas Seith As COO AtriCure; Andy Wade To SVP,2015-01-14 16:06:00-05:00,ATRC,neutral
107270.0,AtriCure Sees FY2015 Sales $122.50M-124.50M,2015-01-12 08:34:00-05:00,ATRC,neutral
107271.0,AtriCure Receives FDA Approval For Pivotal Study to Enroll Non-Paroxysmal Afib Patients ,2014-11-03 12:10:00-05:00,ATRC,positive
107272.0,"AtriCure, Inc. Reports Q3 EPS of $(0.02) vs $(0.17) Est; Revenue of $26.70M vs $25.59M Est",2014-10-30 17:06:00-04:00,ATRC,neutral
107273.0,AtriCure Raises FY14 Revenue Outlook Above Estimates ,2014-10-30 17:04:00-04:00,ATRC,neutral
107274.0,AtriCure Completes Enrollment In Post Approval Study For The Synergy Ablation System,2014-10-09 16:03:00-04:00,ATRC,positive
107275.0,AtriCure Announces the Release of the AtriClip FLEX ,2014-09-18 16:59:00-04:00,ATRC,neutral
107276.0,"Stifel Nicolaus Initiates Coverage on AtriCure, Inc. at Buy, Announces $20.00 PT",2014-05-30 06:38:00-04:00,ATRC,neutral
107277.0,"Stifel Nicolaus Initiates Coverage on AtriCure, Inc. at Buy, Announces $20.00 PT",2014-05-30 06:29:00-04:00,ATRC,neutral
107278.0,AtriCure Announces AtriClip Patent,2014-05-21 16:12:00-04:00,ATRC,neutral
107279.0,"AtriCure, Inc. Reports Q1 EPS of $(0.31) vs $(0.22) Est; Revenue of $24.80M vs $23.36M Est",2014-04-24 16:06:00-04:00,ATRC,neutral
107280.0,"AtriCure, Inc. Reports Q4 EPS of $(0.24) vs $(0.14) Est; Revenue of $21.90M vs $21.16M Est",2014-02-27 16:03:00-05:00,ATRC,neutral
107281.0,UPDATE: AtriCure Announces Commencement of Public Offering of Common Stock,2014-02-12 16:09:00-05:00,ATRC,neutral
107282.0,Atricure Files $150M Mixed Securities Shelf,2014-01-15 13:37:00-05:00,ATRC,positive
107283.0,AtriCure Announces Preliminary Revenue for Q4 $21.9M; Guides FY 2014 Rev $81.9M,2014-01-09 16:05:00-05:00,ATRC,neutral
107284.0,AtriCure Announces Definitive Agreement to Acquire Estech for 2.1M Shares of AtriCure Stock and Up to $26M in Additional Considerations,2013-12-19 16:06:00-05:00,ATRC,positive
107285.0,AtriCure Announces Definitive Agreement To Acquire Estech,2013-12-19 16:06:00-05:00,ATRC,positive
107286.0,"AtriCure, Inc. Reports Q3 EPS of $(0.13) vs $(0.15) Est; Revenue of $20.10M vs $18.30M Est",2013-10-29 16:45:00-04:00,ATRC,neutral
107287.0,AtriCure Appoints Scott Drake to Its Board of Directors ,2013-09-03 16:14:00-04:00,ATRC,neutral
107288.0,"AtriCure, Inc. Reports Q1 EPS of $(0.10) vs $(0.11) Est; Revenue of $19.40M vs $18.62M Est; Reaffirms Outlook",2013-05-02 16:14:00-04:00,ATRC,neutral
107289.0,Atricure Prices 3.475M Shares at $7.25/Share,2013-01-16 09:02:00-05:00,ATRC,positive
107290.0,AtriCure Announces Commencement of Public Offering of Common Stock  ,2013-01-15 16:04:00-05:00,ATRC,neutral
107291.0,AtriCure Sees Q4 Sales ~$18.4M,2013-01-07 08:30:00-05:00,ATRC,neutral
107292.0,UPDATE: Piper Jaffray Upgrades AtriCure to Overweight on New Management Confidence  ,2012-11-16 07:26:00-05:00,ATRC,positive
107293.0,Benzinga's Top Upgrades,2012-11-16 07:07:00-05:00,ATRC,positive
107294.0,"Piper Jaffray Upgrades AtriCure from Neutral to Overweight, Raises PT from $6 to $10",2012-11-16 05:55:00-05:00,ATRC,negative
107295.0,AtriCure Names Michael Carrel President and Chief Executive Officer  ,2012-11-01 16:47:00-04:00,ATRC,neutral
107296.0,AtriCure Reports Q3 EPS $0.27 vs $-0.12 Est; Revenues $86.9M vs $17.29M Est,2012-11-01 16:36:00-04:00,ATRC,neutral
107297.0,"Barrington Research Maintains AtriCure at Outperform, Lowers PT from $17 to $14",2012-08-06 10:15:00-04:00,ATRC,negative
107298.0,UPDATE: Piper Jaffray Downgrades AtriCure from Overweight to Neutral,2012-08-03 09:10:00-04:00,ATRC,negative
107299.0,"Piper Jaffray Downgrades AtriCure from Overweight to Neutral, Lowers PT from $12 to $6",2012-08-03 07:21:00-04:00,ATRC,negative
107300.0,Benzinga's Top Downgrades,2012-08-03 07:19:00-04:00,ATRC,positive
107301.0,AtriCure Reports Q2 EPS $-0.08 vs $-0.08 Est; Revenues $18.3M vs $18.04M Est,2012-08-02 16:27:00-04:00,ATRC,neutral
107302.0,UPDATE: Piper Jaffray Lowers PT to $12 on AtriCure on Decreasing Demand for Microcap Stocks  ,2012-07-03 07:52:00-04:00,ATRC,negative
107303.0,"Piper Jaffray Maintains AtriCure at Overweight, Lowers PT from $14 to $12",2012-07-03 06:20:00-04:00,ATRC,negative
107304.0,William Blair Upgrades AtriCure from Market Perform to Outperform,2012-06-01 06:54:00-04:00,ATRC,neutral
107305.0,AtriCure Reports Q1 EPS $-0.1 vs $-0.14 Est; Revenues $17.5M vs $16.38M Est,2012-05-03 07:40:00-04:00,ATRC,neutral
107306.0,Barrington Research Reiterates AtriCure,2012-02-28 17:40:00-05:00,ATRC,neutral
107307.0,UPDATE: Piper Jaffray Raises Price Target on AtriCure to $14,2012-02-28 10:40:00-05:00,ATRC,neutral
107308.0,"Piper Jaffray Upgrades AtriCure from Neutral to Overweight, Raises PT from $11 to $14",2012-02-28 06:07:00-05:00,ATRC,negative
107309.0,Earnings Scheduled For February 27,2012-02-27 04:27:00-05:00,ATRC,neutral
107310.0,Earnings Scheduled For February 13,2012-02-13 05:03:00-05:00,ATRC,neutral
107311.0,Piper Jaffray Gives Insight to Medical Technology Industry Overview,2012-01-17 09:48:00-05:00,ATRC,neutral
107312.0,AtriCure's Synergy Ablation System Receives FDA Approval for the Treatment of Atrial Fibrillation   ,2011-12-16 08:30:00-05:00,ATRC,positive
107313.0,Canaccord Genuity Maintains Buy Rating and $15.50 PT on AtriCure ,2011-11-18 09:10:00-05:00,ATRC,neutral
107314.0,Barrington Research Reaffirms Outperform on AtriCure,2011-11-02 15:39:00-04:00,ATRC,neutral
107315.0,AtriCure Reports Q3 EPS $(0.07) vs $(0.08) Est; Revenues $15.2M vs $15.88M Est			,2011-11-01 08:46:00-04:00,ATRC,neutral
107316.0,"Barrington Maintains Outperform Rating on AtriCure, $10 PT AFter Positive Panel Vote",2011-10-27 10:25:00-04:00,ATRC,positive
107317.0,FDA Has Concerns About Study on Atricure's Ablation System,2011-10-24 12:30:00-04:00,ATRC,neutral
107318.0,"St. Jude Medical Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-14 17:50:00-04:00,ATRC,neutral
107319.0,Barrington Research Reiterates AtriCure PT,2011-09-19 10:55:00-04:00,ATRC,neutral
107320.0,FDA Panel to Review AtriCure's Synergy Ablation System on October 26,2011-09-19 08:30:00-04:00,ATRC,neutral
107321.0,UPDATE: Piper Jaffray Lowers Price Target On AtriCure To $11,2011-09-02 07:23:00-04:00,ATRC,negative
107322.0,Piper Jaffray Lowers PT On AtriCure To $11,2011-09-02 05:52:00-04:00,ATRC,negative
107323.0,Benzinga's Top Upgrades,2011-08-24 07:42:00-04:00,ATRC,positive
107324.0,"Morgan Keegan Upgrades AtriCure To Outperform, Lowers PT To $13",2011-08-24 06:07:00-04:00,ATRC,negative
107325.0,Morgan Keegan Maintains Market Perform on AtriCure,2011-08-03 07:45:00-04:00,ATRC,neutral
107326.0,Morgan Keenan Comments on AtriCure,2011-07-18 08:36:00-04:00,ATRC,neutral
107327.0,AtriCure Files $50M Mixed Security Shelf,2011-07-01 08:14:00-04:00,ATRC,positive
107328.0,AtriCure Reports Q4 EPS of $0.00 vs. $(0.08),2011-02-16 08:39:00-05:00,ATRC,neutral
107329.0,Barrington's Best Stock Picks for 2011,2011-01-04 14:26:00-05:00,ATRC,positive
107330.0,AtriCure Reports Third Quarter Revenue of $14.5M ,2010-11-02 08:35:00-04:00,ATRC,neutral
107331.0,"NASDAQ Stocks Hitting 52-Week Highs (ATRC, DTPI, LORL, RDCM)",2010-08-24 12:49:00-04:00,ATRC,neutral
107332.0,"Mid-Day Market Movers (ZANE, ATRC, DOVR, IFLG)",2010-06-15 10:47:00-04:00,ATRC,neutral
107333.0,AtriCure (ATRC) Shares Rise On FDA News,2010-05-10 19:23:00-04:00,ATRC,positive
